Dr. Brigitte Poirier is a surgeon-oncologist at the CHU de Québec-Laval University. She is also a clinical researcher at the Research Center of the CHU de Québec-Laval University, and a clinical professor at Laval University School of Medicine. Dr. Poirier is part of the research group of the Centre des Maladies du Sein of CHU de Québec-Laval University.
Using structured breast cancer data
The Centre des Maladies du Sein research team has a comprehensive database of all cancers diagnosed since 1974; more than 12,000 patients are listed. A database of biopsy data from 1999 is also available; data on more than 34,000 biopsies are listed. These databases allow quality publications that modify the management and follow-up of cancers and benign breast diseases.
Offer innovative treatments
The Centre des Maladies du Sein of CHU de Québec-Laval University research group is one of the largest in Canada, offering innovative treatments for breast cancer. More than 50 clinical trials are active at all times and are offered to patients who consult at the clinic or are referred by clinics/hospitals in the area. These clinical trials provide access to innovative experimental medications and develop the expertise of our world-renowned oncologists.
Support the quality of life
The Centre des Maladies du Sein of CHU de Québec-Laval University research group is a pioneer in quality of life studies in breast cancer, from total mastectomy to partial mastectomy, to the use of the cooling cap to counteract hair loss, promoting physical activity to improve survivorship, including optimal preservation of the axillary lymph nodes. The research group is at the forefront of studies promoting quality of life, despite the adverse effects of the disease on an individual’s life.
1050, chemin Sainte-Foy
Centre des maladies du sein Deschênes-Fabia
Canada G1S 4L8
Data not available
Simultaneous quantification of estrogens and glucocorticoids in human adipose tissue by liquid-chromatography-tandem mass spectrometry.Journal Article
J Steroid Biochem Mol Biol, 195 , pp. 105476, 2019, ISSN: 0960-0760.
Axillary Lymph Node Ultrasound Following Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: Results from the SN FNAC Study.Journal Article
Ann Surg Oncol, 26 (13), pp. 4337-4345, 2019, ISSN: 1068-9265.
A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer.Journal Article
Curr Oncol, 26 (1), pp. e70-e80, 2019, ISSN: 1198-0052.
Characteristics and long-term survival of patients diagnosed with pure tubular carcinoma of the breast.Journal Article
J Surg Oncol, 117 (6), pp. 1137-1143, 2018, ISSN: 0022-4790.
In response to: Long-term overall survival of patients diagnosed with pure tubular carcinoma of the breast might be affected by increased co-morbidities.Journal Article
J Surg Oncol, 117 (7), pp. 1615, 2018, ISSN: 0022-4790.
How Wide Should Margins Be for Phyllodes Tumors of the Breast?Journal Article
Breast J, 23 (3), pp. 315-322, 2017, ISSN: 1075-122X.
Association between expression of inflammatory markers in normal breast tissue and mammographic density among premenopausal and postmenopausal women.Journal Article
Menopause, 24 (5), pp. 524-535, 2017, ISSN: 1072-3714.
Five-Year Incidence of Amyotrophic Lateral Sclerosis in British Columbia (2010-2015).Journal Article
Can J Neurol Sci, 43 (6), pp. 791-795, 2016, ISSN: 0317-1671.
Is clinical breast examination important for breast cancer detection?Journal Article
Curr Oncol, 23 (4), pp. e332-9, 2016, ISSN: 1198-0052.
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.Journal Article
Lancet Oncol, 17 (6), pp. 791-800, 2016, ISSN: 1470-2045.
- Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
Recently finished projects
- MA-12: Étude randomisée à double insu visant à comparer le tamoxifène avec un placebo chez les patientes atteintes d'un cancer du sein étendu aux ganglions lymphatiques et qui ont complété une chimiothérapie adjuvante ..., Subvention, L'Institut de recherche de la Société canadienne du cancer, Subvention de recherche, from 1997-04-01 to 2019-03-31
- NSABP Breast Cancer Treatment Protocols, Subvention, National Institute of Health (USA), Subvention de recherche, from 1997-02-01 to 2019-01-31